Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.
Authors
- Marie‐Anne Rameix‐Welti (ORCID: https://orcid.org/0000-0002-5901-3856)
- Cyril Planchais (ORCID: https://orcid.org/0000-0002-5142-7253)
- Emilie Yab
- Vincent Enouf (ORCID: https://orcid.org/0000-0001-7609-4742)
- Florence Guivel‐Benhassine (ORCID: https://orcid.org/0000-0003-3410-5671)
- Delphine Planas (ORCID: https://orcid.org/0000-0002-2509-9954)
- Isabelle Staropoli (ORCID: https://orcid.org/0000-0001-8637-4545)
- Olivier Schwartz (ORCID: https://orcid.org/0000-0002-0729-1475)
- Etienne Simon‐Lorière (ORCID: https://orcid.org/0000-0001-8420-7743)
- Hugo Mouquet (ORCID: https://orcid.org/0000-0002-4230-610X)
- Yannis Rahou
- Frédéric Lemoine (ORCID: https://orcid.org/0000-0001-9576-4449)
- Matthieu Prot (ORCID: https://orcid.org/0000-0003-2337-2491)
- Banujaa Jeyarajah
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Pasteur (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Génomique Bioinformatique et Applications (FR)
- Institut de Recherche Vaccinale (FR)
Publication Details
- Journal
- Pathogens and Immunity
- Published
- 2024-09-30
- DOI
- https://doi.org/10.20411/pai.v10i1.752
- Citations
- 43
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 16.73
Funders
- Agence Nationale de la Recherche
- National Institutes of Health